

**ASX ANNOUNCEMENT**

**New Study Sites Added to Accelerate Patient Recruitment.**

- Five new XanADu Phase II study sites opened in the USA
- Additional sites will further accelerate patient recruitment into the study
- Study sites now total 25 across the USA, Australia and the UK
- On track to complete enrolment into XanADu by the end of 2018

**Sydney, 6 July 2018: Actinogen Medical (ASX: ACW)** is pleased to announce the opening of five (5) new study sites for XanADu, its Phase II clinical trial of Xanamem in mild Alzheimer's disease.

The new sites have been opened in the USA - the region which has proven to be the most productive in terms of patient enrolment to date, and the region with the greatest potential patient population interested in participating in an Alzheimer's clinical trial.

The new sites are in addition to the existing twenty (20) trial sites in the USA, Australia and the UK, that have enrolled 117 patients to date.

"We are delighted with the work being done at our existing trial sites and the quality of these new sites. We are particularly pleased with the new sites enthusiasm to participate in XanADu and their commitment to rapidly identifying patients to enrol into XanADu. Since opening, these new sites have screened a great number of potential new patients. It is expected that the majority of these patients will be enrolled into the trial within the month" said Dr Bill Ketelbey, CEO of Actinogen Medical.

These additional positive developments will ensure XanADu continues on track to complete patient enrolment before the end of 2018 and for the study to read out top-line results by Q2 2019.

**ENDS**

**Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

**Media Enquires**

Zena Chamas

Media & Capital Partners

M: +61 434 153 055

E: [zena.chamas@mcpartners.com.au](mailto:zena.chamas@mcpartners.com.au)

**About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and

is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**